Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome

Low-Dose Naltrexone for the Treatment of Complex Regional Pain Syndrome

The investigators are testing treatment with low-dose naltrexone (LDN) for symptom relief of complex regional pain syndrome (CRPS). Study participants will be randomly assigned to receive either LDN or placebo for a period of several weeks. During this period participants will be asked to attend either in-person or virtual study visits and complete questionnaires.

Inclusion Criteria:

• Upper and/or lower extremity CRPS
• On stable treatment for 1 month
• CRPS for at least 1 year
• Meet the Budapest criteria for CRPS at time of the study.

Exclusion Criteria:

• Any known allergy to naltrexone or naloxone
• Use of prescription opioid analgesics or illegal opioid use
• Current or planned pregnancy.